# Japan approves Sumitomo Pharma's Amchepry, an iPS-cell therapy for Parkinson's, after a 7-patient trial

- Published: 2026-11-14 04:42 UTC
- Section: Life & Health › Medicine
- Tags: Amchepry, Parkinson's disease treatment, iPS cells, induced pluripotent stem cells, Sumitomo Pharma, Japan approval, dopaminergic neurons, accelerated approval, Cuorips ReHeart, Shinya Yamanaka
- URL: https://realtech.media/news/rt-d03f35088bb31032f5298643_japan_approves_sumitomo/

**Japan has approved Amchepry, a therapy based on iPS cells differentiated into dopaminergic neurons, under an accelerated pathway; the trial involved 7 patients.**

![Japan approves Sumitomo Pharma's Amchepry, an iPS-cell therapy for Parkinson's, after a 7-patient trial](https://realtech.media/media/2026/11/86a0121e1d830bc7.jpg)
*National Center for Advancing Translational Sciences from Bethesda, MD, Wikimedia Commons, Public domain*

On 6 March 2026, Sumitomo Pharma announced that it had received Japanese authorisation to manufacture and market Amchepry, a stem-cell therapy for Parkinson's disease, according to science-et-vie.com [1]. The publication describes this as the first authorisation of its kind in the world. The therapy is based on induced pluripotent stem (iPS) cells.

## How the iPS-cell therapy works

Parkinson's disease is neurodegenerative. It involves the progressive destruction of dopaminergic neurons, which produce dopamine, a molecule that controls movement, among other things. As dopamine synthesis fails, patients eventually can no longer write or eat on their own.

Earlier attempts replaced the lost neurons with neurons from fetal tissue. The results were inconsistent: some patients had better mobility, sometimes lasting 15 years, while others saw no effect or developed severe involuntary movements. The approach also depended on rare donations and raised ethical questions.

The discovery of iPS cells in 2006 changed this. They are reprogrammed from adult cells, so no fetuses or embryos are needed. Shinya Yamanaka received the 2012 Nobel Prize in Medicine for this work [1].

## Trial results and open questions

The approval followed an assessment of the treatment's safety and efficacy. The trial included 7 patients with Parkinson's disease, aged 50 to 69. Each received 5 or 10 million iPS cells, previously differentiated into dopaminergic neurons, in the brain. The patients were followed for two years. According to the report, no particular adverse effects were observed, and 4 patients showed improved symptoms [1].

The speed of the approval is debated. Japan has an accelerated approval system for regenerative therapies, which lets companies market a treatment for up to 7 years while studies on its efficacy continue. Some researchers and doctors worry that risks, such as tumours that sometimes follow stem-cell implantation, could be underestimated [1].

Another medical start-up, Cuorips, has received the right to use ReHeart to treat heart failure. According to the publication, Amchepry and ReHeart could be offered to patients as early as this summer [1].

## Sources

1. [science-et-vie.com](https://www.science-et-vie.com/corps-et-sante/traitement-a-base-de-cellules-souches-maladie-de-parkinson-therapie-cellulaire-230498.html)

---

Source: RealTech, realtech.media — https://realtech.media/news/rt-d03f35088bb31032f5298643_japan_approves_sumitomo/